DOP2022000126A - Derivados de furoindazol - Google Patents
Derivados de furoindazolInfo
- Publication number
- DOP2022000126A DOP2022000126A DO2022000126A DO2022000126A DOP2022000126A DO P2022000126 A DOP2022000126 A DO P2022000126A DO 2022000126 A DO2022000126 A DO 2022000126A DO 2022000126 A DO2022000126 A DO 2022000126A DO P2022000126 A DOP2022000126 A DO P2022000126A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compounds
- diseases
- inflammatory
- disorders
- preparing
- Prior art date
Links
- LHTSYIHIIZNLCQ-UHFFFAOYSA-N 1h-furo[2,3-g]indazole Chemical class O1C=CC2=C1C=CC1=C2NN=C1 LHTSYIHIIZNLCQ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000004982 autoimmune uveitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención cubre compuestos de furoindazol de fórmula general (I): (I) en la cual R1, R2, R3, R4, R5, R6, R7a y R7b son como se define en la presente, métodos para preparar dichos compuestos, compuestos intermediarios útiles para preparar dichos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y el uso de dichos compuestos para elaborar composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades autoinmunes tales como esclerosis múltiple, psoriasis, artritis psoriásica, artritis reumatoidea, espondilitis anquilosante, lupus eritematoso sistémico, uveítis autoinmune primaria y secundaria, trastornos inflamatorios como endometriosis, enfermedades oculares inflamatorias, enfermedades renales inflamatorias, enfermedades hepáticas inflamatorias como enfermedades hepáticas no alcohólicas, alcohólicas y de hígado graso tóxicas, enfermedades pulmonares como asma, fibrosis pulmonar idiopática, enfermedad pulmonar obstructiva crónica, y trastornos metabólicos y metabólicoendocrinos como síndrome metabólico, resistencia a la insulina, diabetes mellitus tipo I y tipo II, y trastornos de síndrome de ovario poliquístico (PCOS), trastornos de dolor neuropático e inflamatorio en humanos y animales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19217856 | 2019-12-19 | ||
| PCT/EP2020/085905 WO2021122415A1 (en) | 2019-12-19 | 2020-12-14 | Furoindazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2022000126A true DOP2022000126A (es) | 2022-07-15 |
Family
ID=68965797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000126A DOP2022000126A (es) | 2019-12-19 | 2022-06-15 | Derivados de furoindazol |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230112499A1 (es) |
| EP (1) | EP4077334A1 (es) |
| JP (1) | JP2023508908A (es) |
| KR (1) | KR20220118480A (es) |
| CN (1) | CN115135656B (es) |
| AR (1) | AR120856A1 (es) |
| AU (1) | AU2020408908A1 (es) |
| BR (1) | BR112022011237A2 (es) |
| CA (1) | CA3164963A1 (es) |
| CL (1) | CL2022001644A1 (es) |
| CO (1) | CO2022008338A2 (es) |
| CR (1) | CR20220291A (es) |
| DO (1) | DOP2022000126A (es) |
| EC (1) | ECSP22047527A (es) |
| GE (1) | GEP20247585B (es) |
| IL (1) | IL293968A (es) |
| JO (1) | JOP20220156A1 (es) |
| MX (1) | MX2022007685A (es) |
| PE (1) | PE20221786A1 (es) |
| TW (1) | TW202136271A (es) |
| WO (1) | WO2021122415A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202136240A (zh) | 2019-12-19 | 2021-10-01 | 美商亞文納營運公司 | 用於靶向降解雄激素受體之化合物及方法 |
| EP4298102A1 (en) * | 2021-02-23 | 2024-01-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| WO2022194267A1 (zh) * | 2021-03-18 | 2022-09-22 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| CA3218018A1 (en) * | 2021-04-29 | 2022-11-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| WO2024140969A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| AU5256301A (en) | 2000-04-28 | 2001-11-12 | Yamanouchi Pharmaceutical Co., Ltd. | Froindazole derivative |
| WO2009023773A2 (en) | 2007-08-15 | 2009-02-19 | University Of Miami | Galactokinase inhibitors |
| EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
| WO2010078427A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted pyrazolo [3, 4-b] pyridine compounds |
| US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| WO2014095798A1 (en) | 2012-12-20 | 2014-06-26 | Galapagos Nv | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists) |
| GB201411241D0 (en) | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2016085990A1 (en) | 2014-11-24 | 2016-06-02 | The Regents Of The University Of Michigan | Compositions and methods relating to inhibiting serine hyrdoxymethyltransferase 2 activity |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| EP3594221B1 (en) | 2017-03-06 | 2021-06-30 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Gpr84 receptor antagonist and use thereof |
| US20210177827A1 (en) | 2017-10-25 | 2021-06-17 | Children`S Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
-
2020
- 2020-12-14 JP JP2022537545A patent/JP2023508908A/ja active Pending
- 2020-12-14 AU AU2020408908A patent/AU2020408908A1/en active Pending
- 2020-12-14 EP EP20823813.9A patent/EP4077334A1/en active Pending
- 2020-12-14 TW TW109144136A patent/TW202136271A/zh unknown
- 2020-12-14 BR BR112022011237A patent/BR112022011237A2/pt unknown
- 2020-12-14 CR CR20220291A patent/CR20220291A/es unknown
- 2020-12-14 MX MX2022007685A patent/MX2022007685A/es unknown
- 2020-12-14 JO JOP/2022/0156A patent/JOP20220156A1/ar unknown
- 2020-12-14 CN CN202080097024.7A patent/CN115135656B/zh active Active
- 2020-12-14 GE GEAP202016005A patent/GEP20247585B/en unknown
- 2020-12-14 CA CA3164963A patent/CA3164963A1/en active Pending
- 2020-12-14 US US17/786,268 patent/US20230112499A1/en active Pending
- 2020-12-14 WO PCT/EP2020/085905 patent/WO2021122415A1/en active Application Filing
- 2020-12-14 PE PE2022001093A patent/PE20221786A1/es unknown
- 2020-12-14 KR KR1020227024304A patent/KR20220118480A/ko unknown
- 2020-12-14 IL IL293968A patent/IL293968A/en unknown
- 2020-12-21 AR ARP200103594A patent/AR120856A1/es unknown
-
2022
- 2022-06-14 EC ECSENADI202247527A patent/ECSP22047527A/es unknown
- 2022-06-15 DO DO2022000126A patent/DOP2022000126A/es unknown
- 2022-06-15 CO CONC2022/0008338A patent/CO2022008338A2/es unknown
- 2022-06-16 CL CL2022001644A patent/CL2022001644A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20220156A1 (ar) | 2023-01-30 |
| WO2021122415A9 (en) | 2022-06-30 |
| GEP20247585B (en) | 2024-01-25 |
| IL293968A (en) | 2022-08-01 |
| US20230112499A1 (en) | 2023-04-13 |
| EP4077334A1 (en) | 2022-10-26 |
| ECSP22047527A (es) | 2022-07-29 |
| CR20220291A (es) | 2022-08-10 |
| AU2020408908A1 (en) | 2022-06-30 |
| WO2021122415A1 (en) | 2021-06-24 |
| MX2022007685A (es) | 2022-07-19 |
| CO2022008338A2 (es) | 2022-07-08 |
| BR112022011237A2 (pt) | 2022-08-30 |
| JP2023508908A (ja) | 2023-03-06 |
| CN115135656A (zh) | 2022-09-30 |
| PE20221786A1 (es) | 2022-11-22 |
| CA3164963A1 (en) | 2021-06-24 |
| KR20220118480A (ko) | 2022-08-25 |
| TW202136271A (zh) | 2021-10-01 |
| CN115135656B (zh) | 2024-06-14 |
| CL2022001644A1 (es) | 2023-02-24 |
| AR120856A1 (es) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2022000126A (es) | Derivados de furoindazol | |
| BR112014015142A2 (pt) | di-hidropirimidinoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de distúrbios inflamatórios | |
| AR104178A1 (es) | Derivados de imidazolilmetilo 5-sustituidos | |
| HRP20191756T1 (hr) | Spirociklički inhibitori katepsina c | |
| PA8774101A1 (es) | Compuesto de pirmidina | |
| BR112017022008A2 (pt) | composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios | |
| ATE484497T1 (de) | Sulfonylbenzimidazolderivate | |
| JP2017508816A5 (es) | ||
| AR054084A1 (es) | Derivados de indolcarboxamida y composiciones farmaceuticas que los contienen | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| PA8651501A1 (es) | Derivados de sulfonilbencimidazol | |
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| JP2011508756A5 (es) | ||
| EA201890695A1 (ru) | Новые пиразолилзамещенные гетероарилы и их применение в качестве лекарственных средств | |
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| EA202092678A1 (ru) | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон | |
| JP2012012417A5 (es) | ||
| WO2018071315A3 (en) | Piperidine derivatives as liver x receptor beta agonists, compositions, and their use | |
| JP2017538836A5 (es) | ||
| BR112022002387A2 (pt) | Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| WO2013021284A3 (en) | Anti-il-6 vaccine composition | |
| WO2020047399A8 (en) | Ionizable lipidoids and their uses | |
| AR076516A1 (es) | Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1. | |
| JP2014521710A5 (es) |